2-溴-3-氟甲苯 | 59907-13-0

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟甲苯系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-3-氟甲苯
• 英文名称: 2-bromo-1-fluoro-3-methylbenzene
• 英文别名: 2-bromo-3-fluorotoluene
• CAS: 59907-13-0
• 化学式: C₇H₆BrF
• 分子量: 189.027
• InChiKey: FYCXRRYRNRDSRM-UHFFFAOYSA-N

物化性质

• 熔点：
  118-123℃
• 沸点：
  187°C
• 密度：
  1.503
• 闪点：
  76°(169°F)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2903999090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H227,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-3-fluorotoluene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
H227: Combustible liquid
Keep away from heat/sparks/open flames/hot surfaces. No smoking
P210:
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-3-fluorotoluene
CAS number: 59907-13-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6BrF
Molecular weight: 189.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-3-氟甲苯 在 硼酸三异丙酯 、 叔丁基锂 、 盐酸 作用下， 以 乙醚 、 正戊烷 为溶剂， 反应 1.0h， 以43%的产率得到2-氟-6-甲基苯基硼酸
  参考文献：
  名称：

  New bicyclic compounds as crac channel modulators

  摘要：

  这项发明涉及一种新型化合物，它们是CRAC通道活性的抑制剂。该发明还涉及含有这些化合物的药物组合物，它们的制备方法以及它们在治疗中的应用。

  公开号：

  EP2738172A1
• 作为产物：
  描述：

  2-溴-3-甲基苯胺 在 盐酸 、 hexafluorophosphoric acid 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 0.5h， 生成 2-溴-3-氟甲苯
  参考文献：
  名称：

  WO2006/51410

  摘要：

  公开号：

文献信息

• [EN] AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE<br/>[FR] INHIBITEURS DE L'AUTOTAXINE CONTENANT UN NOYAU À CYCLE BENZYLE-AMIDE CYCLIQUE HÉTÉROAROMATIQUE
  申请人：NOVARTIS AG

  公开号：WO2015008230A1

  公开（公告）日：2015-01-22

  The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

  本发明涉及新型化合物，这些化合物是自体磷脂酶抑制剂，涉及它们的制备方法，含有它们的药物组合物和药物，以及它们在由自体磷脂酶介导的疾病和紊乱中的应用。
• [EN] BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER<br/>[FR] DÉRIVÉS DU BEXAROTÈNE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：DAWN SCIENT PHARMACEUTICALS LLC

  公开号：WO2019169270A1

  公开（公告）日：2019-09-06

  This disclosure relates to compositions and methods for treating cancer. Specifically, this disclosure relates to bexarotene derivatives, methods for treating cancer, autoimmune disorders, and/or skin dermatitis, and/or methods for increasing peripheral blood counts and/or improving immune system function.

  这份披露涉及治疗癌症的组合物和方法。具体而言，这份披露涉及贝沙罗汀衍生物，治疗癌症、自身免疫性疾病和/或皮肤皮炎的方法，以及增加外周血细胞计数和/或改善免疫系统功能的方法。
• [EN] APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'APELINE ET LEURS MÉTHODES D'UTILISATION
  申请人：SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST

  公开号：WO2019032720A1

  公开（公告）日：2019-02-14

  Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.

  本文提供了用于治疗疾病的阿普林受体激动剂。本文披露的化合物对于治疗一系列心血管、肾脏和代谢状况是有用的。
• [EN] FACTOR XIa INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR XIA
  申请人：MERCK SHARP & DOHME

  公开号：WO2017074832A1

  公开（公告）日：2017-05-04

  The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.

  本发明提供了一种化合物（I）的化合物，以及包含一种或多种所述化合物的药物组合物，并且提供了使用所述化合物用于治疗或预防血栓形成、栓塞、高凝血性或纤维变化的方法。这些化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽酶的双重抑制剂。
• [EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS<br/>[FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLINE SUBSTITUÉS UTILES COMME AGONISTES DU GPR120
  申请人：MERCK SHARP & DOHME

  公开号：WO2017205193A1

  公开（公告）日：2017-11-30

  The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

  本发明涉及一种由公式(I)表示的化合物，以及披露了治疗或预防糖尿病、高脂血症、肥胖、非酒精性脂肪肝炎（NASH）、炎症相关疾病及相关疾病和状况有用的药用可接受盐。这些化合物作为G蛋白偶联受体GPR120的激动剂是有用的。还包含了药物组合物和治疗方法。